ストックスクリーナーアプリを入手
25.52
3.66%
-0.97
アフターアワーズ：
25.40
-0.12
-0.47%
前日終値:
$26.49
開ける：
$26.83
24時間の取引高:
1.07M
Relative Volume:
0.46
時価総額：
$2.63B
収益：
$164.01M
当期純損益:
$-65.04M
株価収益率:
-37.15
EPS:
-0.687
ネットキャッシュフロー:
$-383.84M
1週間 パフォーマンス:
+1.67%
1か月 パフォーマンス:
-25.64%
6か月 パフォーマンス:
-7.60%
1年 パフォーマンス:
+29.48%
1日の値動き範囲:
$25.36
$26.93
1週間の範囲:
$24.67
$27.02
52週間の値動き範囲:
$15.60
$38.26
Beam Therapeutics Inc Stock (BEAM) Company Profile
名前
Beam Therapeutics Inc
セクター
電話
857-327-8775
住所
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
25.52 | 2.58B | 164.01M | -65.04M | -383.84M | -0.687 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-20 | 開始されました | Canaccord Genuity | Buy |
| 2025-10-09 | 開始されました | Jefferies | Buy |
| 2025-03-28 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-03-10 | アップグレード | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-07-23 | 開始されました | H.C. Wainwright | Buy |
| 2024-01-29 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-12-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-12-08 | ダウングレード | Jefferies | Buy → Hold |
| 2023-10-20 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | 開始されました | Bernstein | Mkt Perform |
| 2023-02-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-12-20 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | 開始されました | Citigroup | Buy |
| 2022-06-17 | 開始されました | BMO Capital Markets | Market Perform |
| 2022-04-28 | 開始されました | Credit Suisse | Neutral |
| 2022-01-05 | 開始されました | Guggenheim | Buy |
| 2021-10-19 | 開始されました | SVB Leerink | Outperform |
| 2021-09-24 | 再開されました | Stifel | Buy |
| 2021-09-10 | 開始されました | BofA Securities | Buy |
| 2021-05-11 | 開始されました | Redburn | Buy |
| 2021-05-04 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2021-02-16 | 開始されました | Wells Fargo | Overweight |
| 2021-01-29 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-01-06 | 開始されました | Stifel | Hold |
| 2020-08-05 | 開始されました | William Blair | Outperform |
| 2020-03-02 | 開始されました | Barclays | Overweight |
| 2020-03-02 | 開始されました | JP Morgan | Overweight |
| 2020-03-02 | 開始されました | Jefferies | Buy |
| 2020-03-02 | 開始されました | Wedbush | Outperform |
すべてを表示
Beam Therapeutics Inc (BEAM) 最新ニュース
Beam Therapeutics (BEAM) insider Amy Simon plans sale of 16,677 common shares - Stock Titan
Beam Therapeutics (BEAM) Revenue BreakdownMain Composition - Moomoo
TradingKey - TradingKey
Beam Therapeutics Inc (BEAM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Beam Therapeutics Inc (BEAM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BEAM|Beam Therapeutics Inc|Price:25.100|Chg%:-0.810 - TradingKey
Beam Therapeutics Inc (BEAM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Beam Therapeutics Inc (BEAM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Beam Therapeutics Inc. (BEAM) stock price, news, quote and history - Yahoo Finance Australia
First Trust Heitman Glbl Prm Rl Estt ETF (PRME) stock price, news, quote and history - Yahoo Finance UK
Beam Therapeutics Inc (BEAM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Beam Therapeutics Inc. (BEAM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Beam Therapeutics to present BEAM-302 data at September conference By Investing.com - Investing.com Nigeria
Beam Therapeutics to present BEAM-302 data at September conference - Investing.com
Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 - The Manila Times
Beam's One-Time Alpha-1 Treatment Data Update Set for Sept. 8 - Stock Titan
Beam Therapeutics Stock 9-Day Losing Spree: Stock Falls 31% - Trefis
9 Red Days In A Row: Beam Therapeutics Stock Is Down 31% - Trefis
8 Red Days In A Row: Beam Therapeutics Stock Is Down 27% - Trefis
Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead? - The Motley Fool
ETFs Investing in Beam Therapeutics, Inc. Stocks - TradingView
8-Day Sell-Off Sends Beam Therapeutics Stock Down 27% - Trefis
Understanding the Setup: (BEAM) and Scalable Risk - Stock Traders Daily
BEAM Stock's Gains Fade Despite Promising Data Rare Liver Disease Treatment Data - Stocktwits
Beam Therapeutics Stock 6-Day Losing Spree: Stock Falls 19% - Trefis
6 Red Days In A Row: Beam Therapeutics Stock Is Down 19% - Trefis
Bank of America Securities Maintains Buy Rating for Beam Therapeutics (BEAM) - Yahoo Finance
Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics - Yahoo Finance
4 Best CRISPR Companies to Buy in 2026 and How to Invest - The Motley Fool
BEAM News | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill
What Were the Key Highlights from Beam's RBC Conference Presentation - Kavout | AI
Prime Medicine gains after winning arbitration with Beam Therapeutics - MSN
Beam Therapeutics Inc. (BEAM) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Beam Therapeutics (BEAM) Short Interest & Short Float | Updated Jul 2026 - MarketBeat
Beam Therapeutics (BEAM) Faces New AATD Rival PM647 Ruling What Does It Signal Strategically? - Yahoo Finance
Prime Editing Clears IP Fight, Sets Q3 Filing for First Liver-Targeted AATD Drug - Tech Times
Prime Medicine Beats Beam Therapeutics In Patent DisputeBut Both Are Investable (PRME) - Seeking Alpha
BofA Securities Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $47 - Moomoo
BEAM Reiterated by B of A Securities -- Price Target Maintained at $47 - GuruFocus
Prime Medicine Jumps 15% as Arbitration Win Clears Path for AATD Gene-Editing Human Trials - finance.biggo.com
TD Cowen reiterates Buy on Prime Medicine stock after arbitration win By Investing.com - Investing.com South Africa
Prime Medicine Receives Favorable Ruling in Beam Therapeutics License Arbitration; Shares Rise - marketscreener.com
Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics Case - Benzinga
PRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drug - Stocktwits
BofA reiterates Beam Therapeutics stock rating after arbitration ruling By Investing.com - Investing.com Nigeria
BofA reiterates Beam Therapeutics stock rating after arbitration ruling - Investing.com
Prime Medicine wins binding arbitration against Beam Therapeutics - grafa.com
Prime Medicine stock surges after winning arbitration with Beam By Investing.com - Investing.com South Africa
Why is Beam Therapeutics stock sliding today? By Investing.com - Investing.com Canada
Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics - The Manila Times
Prime Medicine (NASDAQ: PRME) cleared of breach in Beam arbitration ruling - Stock Titan
Beam Therapeutics Inc (BEAM) 財務データ
収益
当期純利益
現金流量
EPS
2.44%
0.02%
大文字化:
|
ボリューム (24 時間):